Pre-Open Movers 05/05: (CHMA) (ATNX) (IBIO) Higher; (COCP) (ESPR) (MCFE) Lower (more...)
Get Alerts AMYT Hot Sheet
Join SI Premium – FREE
Chiasma, Inc. (Nasdaq: CHMA) 41% HIGHER; Amryt (Nasdaq: AMYT) announces that it has signed a definitive agreement to acquire Chiasma, Inc. (Nasdaq: CHMA) in an all-stock combination. The combined company will be a global leader in rare and orphan diseases with three on-market commercial products, a global commercial and operational footprint and a significant development pipeline of therapies with the financial flexibility to execute its growth plans. The transaction has been approved and recommended by the Boards of both Amryt and Chiasma.
Athenex, Inc., (NASDAQ: ATNX) 33.4% HIGHER; announced that it has acquired Kuur Therapeutics, Inc., the leading developer of off-the-shelf CAR-NKT cell immunotherapies for the treatment of solid and hematological malignancies.
Cocrystal Pharma, Inc. (NASDAQ: COCP) 27.5% LOWER; entered into an underwriting agreement with H.C. Wainwright & Co., LLC under which the underwriter has agreed to purchase on a firm commitment basis 26,000,000 shares of common stock of the Company, at a price to the public of $1.54 per share, less underwriting discounts and commissions. The closing of the offering is expected to occur on or about May 7, 2021, subject to satisfaction of customary closing conditions.
iBio, Inc. (NYSE: IBIO) 24% HIGHER; announced today that it has successfully resolved its lawsuit with Fraunhofer USA, Inc. (“Fraunhofer USA”). The parties’ settlement confirms iBio’s ownership of certain intellectual property related to plant-based biopharmaceutical production. As part of the settlement, iBio granted Fraunhofer USA a fully paid-up license to use the recombinant protein manufacturing technologies that were the subject of litigation.
Esperion Therapeutics (NASDAQ: ESPR) 22% LOWER; reported Q1 EPS of ($3.50), $0.98 worse than the analyst estimate of ($2.52). Revenue for the quarter came in at $8 million versus the consensus estimate of $22.03 million.
Ault Global Holdings, Inc. (NYSE: DPW) 20.8% HIGHER; Revenue of approximately $13 million, an increase of approximately 132% from $5.6 million in the prior first fiscal quarter.
Veru Inc. (NASDAQ: VERU) 20.5% HIGHER; announced that the clinical results from the Phase 2 clinical study of enobosarm, an oral selective androgen receptor targeting agonist, in heavily pretreated women with AR+ER+HER2- advanced breast cancer including further efficacy data and an analysis of patients who have failed both estrogen blocking agents and CDK 4/6 inhibitors, will be presented at the European Society for Medical Oncology (ESMO) Breast Cancer Virtual Congress 2021 to be held May 05-08, 2021.
DAVIDsTEA Inc. (Nasdaq: DTEA) 13% HIGHER; announces that it will seek authorization from the Québec Superior Court on Friday, May 7, 2021 to file its Plan of Arrangement under the Companies’ Creditors Arrangement Act (“CCAA”) and to call a creditors’ meeting to be held on June 11, 2021. The Plan of Arrangement to be submitted to the creditors for approval provides that DAVIDsTEA will distribute an aggregate amount of approximately CDN $18 million to its creditors and those of DAVIDsTEA (USA) Inc., the Company’s wholly-owned U.S. subsidiary, in full and final settlement of all claims affected by the Plan of Arrangement.
The ODP Corporation (NASDAQ: ODP) 9.6% HIGHER; announced today that its Board of Directors has unanimously approved a plan to pursue a separation of the Company into two independent, publicly traded companies, each with a unique and highly focused strategy and investment profile:
Alteryx (NYSE: AYX) 9.3% HIGHER; reported Q1 EPS of ($0.08), $0.15 better than the analyst estimate of ($0.23). Revenue for the quarter came in at $118.8 million versus the consensus estimate of $106.11 million. Alteryx sees FY2021 EPS of ($0.27)-($0.24), versus the consensus of ($0.21). Alteryx sees FY2021 revenue of $111-114 million, versus the consensus of $111.37 million. Alteryx sees FY2021 EPS of ($0.07)-$0.07, versus the consensus of $0.02. Alteryx sees FY2021 revenue of $565-575 million, versus the consensus of $560.25 million.
Caesars Entertainment (NASDAQ: CZR) 8.3% HIGHER; reported Q1 EPS of ($2.03), $0.23 worse than the analyst estimate of ($1.80). Revenue for the quarter came in at $1.7 billion versus the consensus estimate of $1.7 billion.
Tupperware Brands (NYSE: TUP) 8% HIGHER; reported Q1 EPS of $0.82, $0.28 better than the analyst estimate of $0.54. Revenue for the quarter came in at $460.3 million versus the consensus estimate of $434.05 million.
Lyft (NASDAQ: LYFT) 6.9% HIGHER; reported Q1 EPS of ($1.31), which does not compare to the analyst estimate of ($0.53). Revenue for the quarter came in at $609 million versus the consensus estimate of $558.7 million.
Kar Auction Services (NYSE: KAR) 6.8% HIGHER; reported Q1 EPS of $0.45, $0.34 better than the analyst estimate of $0.11. Revenue for the quarter came in at $581.6 million versus the consensus estimate of $555.55 million. 2021 GuidanceThe company's previously stated guidance remains unchanged.
Match Group (NASDAQ: MTCH) 6.2% HIGHER; reported Q1 EPS of $0.57, $0.17 better than the analyst estimate of $0.40. Revenue for the quarter came in at $668 million versus the consensus estimate of $650.66 million. Match Group sees Q2 2021 revenue of $680-690 million, versus the consensus of $678.8 million.
Activision Blizzard (NASDAQ: ATVI) 6% HIGHER; reported Q1 EPS of $0.98, $0.28 better than the analyst estimate of $0.70. Revenue for the quarter came in at $2.28 billion versus the consensus estimate of $1.78 billion. Activision Blizzard sees Q2 2021 EPS of $0.91, versus the consensus of $0.75. Activision Blizzard sees Q2 2021 revenue of $2.135 billion, versus the consensus of $1.81 billion. Activision Blizzard sees FY2021 EPS of $3.42, versus the consensus of $3.65. Activision Blizzard sees FY2021 revenue of $8.37 billion, versus the consensus of $8.55 billion.
Community Health (NYSE: CYH) 5.4% HIGHER; Jefferies upgraded from Hold to Buy with a price target of $18.00 (from $11).
Herbalife Nutrition (NYSE: HLF) 4.7% HIGHER; reported Q1 EPS of $1.42, $0.33 better than the analyst estimate of $1.09. Revenue for the quarter came in at $1.5 billion versus the consensus estimate of $1.44 billion. Herbalife Nutrition sees FY2021 EPS of $4.65-$5.05, versus the consensus of $4.63. Herbalife Nutrition sees Q2 2021 EPS of $1.22-$1.37, versus the consensus of $1.24.
Zillow (NASDAQ: Z)(NASDAQ: ZG) 4.6% HIGHER; reported Q1 revenue for the quarter came in at $1.2 billion versus the consensus estimate of $1.1 billion.
McAfee Corp. (NASDAQ: MCFE) 3.7% LOWER; reported Q1 EPS of $0.25, which may not compare to the analyst estimate of $0.36. Revenue for the quarter came in at $773 million versus the consensus estimate of $732.23 million.
Infinera (NASDAQ: INFN) 3.5% HIGHER; reported Q1 EPS of ($0.03), $0.03 better than the analyst estimate of ($0.06). Revenue for the quarter came in at $331.9 million versus the consensus estimate of $331.49 million. Infinera sees Q2 2021 revenue of $344 million, versus the consensus of $341.2 million.
Upwork Inc. (NASDAQ: UPWK) 1.7% LOWER; reported Q1 EPS of $0.03, $0.07 better than the analyst estimate of ($0.04). Revenue for the quarter came in at $113.6 million versus the consensus estimate of $108.65 million.
Exact Sciences (NASDAQ: EXAS) 1.5% LOWER; reported Q1 EPS of ($0.18), $0.85 better than the analyst estimate of ($1.03). Revenue for the quarter came in at $402.1 million versus the consensus estimate of $388.57 million. Exact Sciences sees Q2 2021 revenue of $1.69-1.735 billion, versus the consensus of $1.72 billion.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Diversified Energy (DEC) to Acquire Oaktree's Interest in Indigo, Tanos III, East Texas, and Tapstone
- Mobix Labs (MOBX) Secures $100M Committed Equity Facility
- Midday movers: Google, Pepsi rise; Boeing, Zillow fall
Create E-mail Alert Related Categories
Special ReportsRelated Entities
Jefferies & Co, Pre-Open Losers, Pre-Open Winners, Definitive Agreement, Pre Market Movers, H.C. WainwrightSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!